Last updated: February 16, 2026
Drug Overview
NDC 57237-0157 is identified as Xadago (safinamide). Approved by the FDA in 2017, it is used as an adjunct therapy for Parkinson’s disease. The drug belongs to the monoamine oxidase B inhibitor (MAO-B inhibitor) class, specifically designed to manage motor fluctuations.
Market Size and Dynamics
- Prevalence of Parkinson’s Disease: Estimated to affect 1 million Americans, with the global market exceeding 8 million patients. The growing aging population sustains demand for Parkinson’s treatments.
- Market Penetration: As of 2022, Xadago accounts for a modest portion of the Parkinson’s adjunct therapy market, which is dominated by levodopa, dopamine agonists, and other MAO-B inhibitors like rasagiline.
- Competitive Landscape: Limited direct competition; main rivals include rasagiline (Azilect by Teva/Astellas) and safinamide’s potential generics.
Sales and Revenue Trends
- Sales Data (2022): U.S. sales approximated $50-70 million. Global sales likely double this, considering European and Asian markets.
- Growth Drivers: Increased diagnosis rates, growing awareness, and expanded indications. The approval of generic versions could significantly alter pricing and market penetration.
Pricing and Cost Factors
- Brand Price: In the U.S., retail prices for branded safinamide hover around $650-$750 for a 30-count, 50 mg tablets, translating to roughly $20-$25 per tablet.
- Generic Entry: As of late 2022, multiple generics received FDA approval, leading to an anticipated price decrease of 40-60% over the next 1-2 years.
Regulatory and Reimbursement Environment
- FDA Approval: Secured for adjunct therapy in Parkinson’s disease for patients inadequately controlled on levodopa.
- Insurance Coverage: Favorable with Medicare Part D and private insurers, but formulary status and co-payments vary.
- Pricing Regulations: No direct price controls; however, generic competition and pharmacy benefit management influence net prices.
Price Projections (2023-2027)
| Year |
Estimated Branded Price |
Expected Generic Price |
Market Share of Generic |
Notes |
| 2023 |
$20-$25 per tablet |
$10-$15 per tablet |
10-20% |
Post-generic approval, initial uptake moderate |
| 2024 |
$15-$20 per tablet |
$5-$10 per tablet |
25-40% |
Continued generic market expansion |
| 2025 |
$12-$15 per tablet |
$3-$8 per tablet |
50-70% |
Generic dominance increases profit compression |
| 2026 |
$10-$12 per tablet |
$2-$5 per tablet |
70-80% |
Price stabilization at lower levels |
| 2027 |
$8-$10 per tablet |
$2-$4 per tablet |
>80% |
Market predominantly generic, margins decrease |
Factors Influencing Future Pricing
- Patent Status: Patent expirations scheduled for 2024-2025 will facilitate generic entry.
- Market Demand: Increasing Parkinson’s prevalence sustains demand, but price sensitivity among payers limits upside for branded sales.
- Manufacturing Costs: Stable, with potential reductions due to scale economies and generic manufacturing efficiencies.
- Regulatory Changes: No current movement towards price regulation; reliance on market forces.
Key Takeaways
- The Parkinson’s adjunct therapy market remains steady, with Xadago capturing a niche share.
- Generics are poised to sharply reduce prices over the next 2 years.
- Branded prices are likely to decline by up to 60%, while volume increases may partially offset lower margins.
- The overall market size continues to grow, supported by Parkinson’s disease prevalence and evolving treatment protocols.
- Strategic positioning around patent expiration and generics is critical for future valuation.
FAQs
-
What factors will most impact Xadago’s price in the coming years?
Patent expiry, generic market entry, and payer negotiations significantly influence pricing.
-
How does Xadago compare to other MAO-B inhibitors?
It offers a different dosing and side effect profile, with similar efficacy, but market share is smaller.
-
What is the expected market share of Xadago in 2027?
Market share projected below 10% in Parkinson’s adjunct therapy, dominated by generics and other branded competitors.
-
Are there emerging therapies that could replace safinamide?
New drugs targeting Parkinson’s motor symptoms and neuroprotection are in development but are not yet approved.
-
What is the potential for global expansion?
Growth potential exists, especially in Europe, Asia, and Latin America, where Parkinson’s treatments are less saturated.
Cited Sources:
[1] IQVIA, Market Insider, 2022.
[2] FDA Database, 2017-2023.
[3] EvaluatePharma, 2022.
[4] Parkinson's Foundation, 2023.
[5] Transparency Market Research, 2022.
